Panagora Asset Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Panagora Asset Management’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-11,245	Closed	-$54K	–	2818
2019 Q2	$54K	Sell	11,245 -626	-5%	-$2.97K	﹤0.01%	2078
2019 Q1	$65K	Hold	11,871	–	–	﹤0.01%	1989
2018 Q4	$36K	Buy	+11,871	New	+$41.2K	﹤0.01%	2061
2016 Q2	–	Sell	-1,649	Closed	-$109K	–	2394
2016 Q1	$109K	Buy	1,649 +1,278	+344%	+$66.7K	﹤0.01%	1836
2015 Q4	$23K	Sell	371 -1,977	-84%	-$139K	﹤0.01%	2129
2015 Q3	$157K	Buy	2,348 +446	+23%	+$36.4K	﹤0.01%	1680
2015 Q2	$185K	Buy	+1,902	New	+$181K	﹤0.01%	1725
2014 Q1	–	Sell	-486	Closed	-$20K	–	2405
2013 Q4	$20K	Sell	486 -143	-23%	-$4.15K	﹤0.01%	2098
2013 Q3	$19K	Sell	629 -519	-45%	-$18.2K	﹤0.01%	2199
2013 Q2	$61K	Buy	+1,148	New	+$50.3K	﹤0.01%	1973

Other funds holding MACK

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

WSL

Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Panagora Asset Management's MACK Position: Q3 2019 in Review

Panagora Asset Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2019, closing a stake of 11,245 shares — an estimated $54K sold.

Panagora Asset Management first reported a position in MACK in Q2 2013 and held it in 10 quarters. The position peaked at $185K in Q2 2015. 47 funds tracked by Wall St. Rank hold MACK as of Q3 2019.

Panagora Asset Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
Panagora Asset Management sold 11,245 Merrimack Pharmaceuticals, Inc. shares in Q3 2019, an estimated $54K.
Panagora Asset Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 10 quarters.
Panagora Asset Management's Merrimack Pharmaceuticals, Inc. position peaked at $185K in Q2 2015.
47 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2019.

Based on Panagora Asset Management's 13F filing for Q3 2019, filed 12 Nov 2019.